Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment

BMJ. 2003 May 24;326(7399):1118. doi: 10.1136/bmj.326.7399.1118.

Abstract

Objective: To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia.

Design: Randomised controlled trial.

Setting: Hospital gastroenterology unit.

Participants: 219 patients under 45 years old presenting with dyspepsia without alarm symptoms.

Intervention: Patients received treatment with omeprazole 20 mg (group A) or with a urea breath test followed by an eradication treatment in case of H pylori infection or omeprazole alone in non-infected patients (group B). Lack of improvement or recurrence of symptoms prompted endoscopy.

Main outcome measures: Improvement in symptoms assessed by a dyspepsia severity score every two months; use of medical resources (endoscopic workload and medical consultation); clinical outcome.

Results: 96/109 (88%) patients in group A and 61/110 (55%) in group B (P < 0.0001) had endoscopy: in 19 patients in group A and 32 in group B (20/67 infected and 12/43 non-infected) because of no improvement; in 77 further patients in group A and 29 in group B (7 infected and 22 non-infected) because of recurrence of symptoms during follow up. Endoscopy showed peptic ulcers only in group A; oesophagitis occurred significantly more often in group B than in group A. About 80% of examinations were normal in both groups, but nine duodenal scars occurred in group A.

Conclusions: Eradication treatment allows resolution of symptoms in a large number of patients with dyspepsia and reduces the endoscopic workload. After a trial of omeprazole, symptoms recur in nearly every patient. Such treatment is also likely to mask an appreciable number of peptic ulcers and cases of oesophagitis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anti-Ulcer Agents / therapeutic use*
  • Dyspepsia / drug therapy*
  • Dyspepsia / microbiology
  • Endoscopy, Gastrointestinal
  • Female
  • Helicobacter Infections / complications*
  • Helicobacter pylori*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Patient Compliance
  • Recurrence

Substances

  • Anti-Ulcer Agents
  • Omeprazole